Rakesh R Ramjiawan
Overview
Explore the profile of Rakesh R Ramjiawan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
1091
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gupta N, Ochiai H, Hoshino Y, Klein S, Zustin J, Ramjiawan R, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831366
Radiotherapy (RT) is a standard treatment for patients with advanced prostate cancer (PCa). Previous preclinical studies showed that SDF1α/CXCR4 axis could mediate PCa metastasis (most often to the bones) and...
2.
Li W, Li S, Chen I, Liu Y, Ramjiawan R, Leung C, et al.
Radiat Oncol
. 2021 Mar;
16(1):48.
PMID: 33663521
Background: Patients with metastatic HER2/neu-positive (HER2/neu +) breast cancer (BC) often experience treatment resistance, disease recurrences and metastases. Thus, new approaches for improving the treatment of HER2/neu + BC to...
3.
Aoki S, Inoue K, Klein S, Halvorsen S, Chen J, Matsui A, et al.
Gut
. 2021 Jan;
71(1):185-193.
PMID: 33431577
Objective: Intrahepatic cholangiocarcinoma (ICC)-a rare liver malignancy with limited therapeutic options-is characterised by aggressive progression, desmoplasia and vascular abnormalities. The aim of this study was to determine the role of...
4.
Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen I, et al.
J Immunother Cancer
. 2020 Nov;
8(2).
PMID: 33234602
Background And Purpose: Combining inhibitors of vascular endothelial growth factor and the programmed cell death protein 1 (PD1) pathway has shown efficacy in multiple cancers, but the disease-specific and agent-specific...
5.
Millar D, Ramjiawan R, Kawaguchi K, Gupta N, Chen J, Zhang S, et al.
Nat Biotechnol
. 2020 Feb;
38(4):420-425.
PMID: 32042168
Several cancer immunotherapy approaches, such as immune checkpoint blockade and adoptive T-cell therapy, boost T-cell activity against the tumor, but these strategies are not effective in the absence of T...
6.
Shigeta K, Datta M, Hato T, Kitahara S, Chen I, Matsui A, et al.
Hepatology
. 2019 Aug;
71(4):1247-1261.
PMID: 31378984
Background And Aims: Activation of the antitumor immune response using programmed death receptor-1 (PD-1) blockade showed benefit only in a fraction of patients with hepatocellular carcinoma (HCC). Combining PD-1 blockade...
7.
Kodack D, Askoxylakis V, Ferraro G, Sheng Q, Badeaux M, Goel S, et al.
Sci Transl Med
. 2017 May;
9(391).
PMID: 28539475
Although targeted therapies are often effective systemically, they fail to adequately control brain metastases. In preclinical models of breast cancer that faithfully recapitulate the disparate clinical responses in these microenvironments,...
8.
Ramjiawan R, Griffioen A, Duda D
Angiogenesis
. 2017 Apr;
20(2):185-204.
PMID: 28361267
Angiogenesis is defined as the formation of new blood vessels from preexisting vessels and has been characterized as an essential process for tumor cell proliferation and viability. This has led...
9.
Chen Y, Liu Y, Sung Y, Ramjiawan R, Lin T, Chang C, et al.
Sci Rep
. 2017 Mar;
7:44123.
PMID: 28276530
Sorafenib is a RAF inhibitor approved for several cancers, including hepatocellular carcinoma (HCC). Inhibition of RAF kinases can induce a dose-dependent "paradoxical" upregulation of the downstream mitogen-activated protein kinase (MAPK)...
10.
Reiberger T, Chen Y, Ramjiawan R, Hato T, Fan C, Samuel R, et al.
Nat Protoc
. 2015 Jul;
10(8):1264-74.
PMID: 26203823
Subcutaneous xenografts have been used for decades to study hepatocellular carcinoma (HCC). These models do not reproduce the specific pathophysiological features of HCCs, which occur in cirrhotic livers that show...